Krishna Rao, MD

Krishna Rao, MD

Associate Professor, Hematology/Oncology, Department of Internal Medicine
Internal Medicine
Languages:
English, Kannada

    About me

    Gender

    Male

    Additional languages spoken

    Kannada

    Education & training

    Positions
    Oncologist
    Board Certifications
    Hematology
    Medical Oncology
    Medical School
    University of Miami, Miami, Florida
    Residency
    Mayo Medical School, Rochester, Minnesota - Internal Medicine
    Fellowship
    Fred Hutchinson Cancer Research Center, Seattle, Washington - Hematology/Medical Oncology

    Research

    Research Interests
    ENT Tumors, Breast Cancer, Melanoma, Skin Cancer as well as Head and Neck Cancer.

    Publications

    Protocol for phase I study of pembrolizumab in combination with Bacillus Calmette-Guérin for patients with high-risk non-muscle invasive bladder cancer. ML Jamil, M Deebajah, A Sood, K Robinson, K Rao, S Sana, S Alanee BMJ open 9 (7), e028287, 2019.

    Anusha Kallurkar, Shreedhar Kulkarni, Kristin Delfino, Daniel Ferraro, and Krishna Rao, “Characteristics of Chronic Pain among Head and Neck Cancer Patients Treated with Radiation Therapy: A Retrospective Study,” Pain Research and Management, vol. 2019, Article ID 9675654, 8 pages, 2019.

    Joshi P., Modur V., Cheng J-M, Robinson K., Rao K., Characterization of immortalized human mammary epithelial cell line HMEC 2.6. Tumor Biology 2017, 39(10): 1-12.

    Iqbal, Muhammad Fahair; Agamah, Edem; Rao, Krishna. Overall Survival in Stage III and IV High  Risk Head and Neck Squamous Cell Carcinoma Patients who received Adjuvant Chemotherapy and Radiation without Cisplatin. Cancer and Clinical Oncology, [S.l.], v. 7, n. 1, p.1-11, Nov. 2017.

    CD24 expression may play a role as a predictive indicator and a modulator of cisplatin treatment response in head and neck squamous cellular carcinoma" Vishnu Modur, Pooja Joshi, Daotai Nie, Thomas. K. Robbins, Aziz U. Khan, Krishna Rao. 2016 Jun 8;11(6):e0156651. doi: 10.1371/journal.pone.0156651. eCollection 2016

    AKR1B10 Promotes Breast Cancer Metastasis through Integrin α5/δ-Catenin mediated FAK/Src/Rac1 Signaling Pathway" by Chenfei Huang, Steven Verhulst, Yi Shen, Yiwen Bu, Yu Cao, Yingchun He, Dan Huang, Chun Cai, Krishna Rao, Duanfang Liao, Junfei Jin, and Deliang Cao. 2016 Jul 12;7(28):43779-43791. doi: 10.18632/oncotarget.9672.

    Rogers, LQ; Verhulst, S; Rao, K; Malone, J; Robbs, R; Robbins, TK. Developing theory-based measurement tools for improving diet compliance in head and neck cancer patients. Journal of Food and Nutritional Disorders. 2015;4:2 (open access).

    Timme DW, Jonnalagadda S, Patel R, Rao K, Robbins KT. Treatment Selection for T3/T4a Laryngeal Cancer: Chemoradiation Versus Primary Surgery. Ann Otol Rhinol Laryngol. 2015 Nov;124(11):845- 51.

    Rogers, LQ; Fogleman, A; Verhulst, S; Bhugra, M; Rao, K; Malone, J; Robbs, R; Robbins, KT Refining measurement of social cognitive theory factors associated with exercise adherence in head and neck cancer patients. J Psychosoc Oncol. 2015;33(5):467-87.

    Rao K, Robinson K, Malone J, Clausen C, Shevlin B, and K Thomas Robbins (2015) A Pilot Study of Induction Triplet Chemotherapy Followed by Minimally Invasive Surgery for Stage 3-4 Resectable Oropharyngeal Cancer. Otolaryngol (Sunnyvale) 5: 196.

    Clinical trials

    Trial
    Internal Medicine

    A Phase 1 Study of SGN-B6A in Advanced Solid Tumors

    Active recruiting

    This trial looks at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors (NSCLC, HNSCC).

    Contact: Kathy Robinson 217-545-1946
    Trial
    Urology

    A Randomized Open-Label Phase 2/3 Study of BT8009 Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

    Active recruiting

    The main objective of the study is to measure how safe and effective BT8009 (zelenectide pevedotin) is when used alone and in combination with pembrolizumab in participants with locally advanced or metastatic urothelial cancer (UC).

    Contact: Kathy Robinson 217-545-1946
    Trial
    Simmons Cancer Institute

    EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk

    Active recruiting

    The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-).

    Contact: Kathy Robinson 217-545-1946
    Trial
    Simmons Cancer Institute

    A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer

    Active recruiting

    The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).

    Contact: Kathy Robinson 217-545-1946